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Abstract
Mammalian cells have cytoplasmic and mitochondrial aminoacyl-tRNA synthetases
(ARSs) that catalyze aminoacylation of tRNAs during protein synthesis. Despite their
housekeeping functions in protein synthesis, recently, ARSs and ARS-interacting multi-
functional proteins (AIMPs) have been shown to play important roles in disease patho-
genesis through their interactions with disease-related molecules. However, there are
lacks of data resources and analytical tools that can be used to examine disease associ-
ations of ARS/AIMPs. Here, we developed an Integrated Database for ARSs (IDA), a
resource database including cancer genomic/proteomic and interaction data of ARS/
AIMPs. IDA includes mRNA expression, somatic mutation, copy number variation and
phosphorylation data of ARS/AIMPs and their interacting proteins in various cancers.
IDA further includes an array of analytical tools for exploration of disease association of
ARS/AIMPs, identification of disease-associated ARS/AIMP interactors and reconstruc-
tion of ARS-dependent disease-perturbed network models. Therefore, IDA provides both
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comprehensive data resources and analytical tools for understanding potential roles of
ARS/AIMPs in cancers.
Database URL: http://ida.biocon.re.kr/, http://ars.biocon.re.kr/
Introduction
Cells have an array of cytoplasmic and mitochondrial
aminoacyl-tRNA synthetases (ARSs) that are involved in
cellular protein synthesis. ARSs catalyze the ligation of
amino acids to their cognate tRNAs during protein synthe-
sis. Thus, ARSs have been considered as housekeepers
involved in protein synthesis, being less sensitive to system
perturbation compared with signal mediators or transcrip-
tional factors that are fully dedicated to system control.
However, recently, aberrant expression, mislocalization
and variant formation of ARSs have been observed in
various cancer cells (1). For this reason, more attention is
being paid to potential roles of ARS/ARS-interacting multi-
functional proteins (AIMPs) in system regulation and
pathogenesis of various diseases.
Mammalian ARSs contain additional domains attached
to their catalytic domains, compared with prokaryotic
counterparts (2). Using these additional domains, they
interact with other molecules to form diverse complexes,
thereby affecting activities of disease-related cellular proc-
esses (3). More intriguingly, several mammalian ARSs
form a macromolecular protein complex with three non-
enzymatic factors named AIMPs (4, 5). Although they are
not the enzymes like ARSs, they are considered as the
members of the ARS community since they play critical
scaffolding role in the structural integrity of the multi-
tRNA synthetase complex (MSC). Thus, we consider three
AIMPs together with 20 cytosolic ARSs as the same
community group. A growing volume of evidence shows
that ARS/AIMPs are closely associated with disease patho-
genesis through their interactions with disease-related
molecules (1, 6). These data indicate that alterations in
interactions of ARS/AIMPs, together with abnormal
expression and mislocalization of ARS/AIMPs, can lead to
perturbation of disease-related cellular networks.
Huge amounts of genomic, transcriptomic, proteomic
and interaction data for diverse diseases have been
accumulated. Recently, the importance of ARS/AIMPs in
cancer pathogenesis has been addressed in a series of publi-
cations (7–14). Thus, we previously reviewed potential
roles of ARS/AIMPs in various cancers by reanalyzing
previously published global datasets (1). However, explor-
ation of abnormal expression and interaction of ARS/
AIMPs in these diseases is limited due to the lack of
comprehensive resources that can be used to effectively
navigate and explore alterations in genomic, tran-
scriptomic and proteomic data and also in interactions of
ARS/AIMPs in various diseases. Furthermore, there is a
severe lack of analytical tools that can be used to analyze
associations of ARS/AIMPs with human diseases and to re-
construct ARS/AIMP-dependent disease-perturbed net-
work models. Here, we present an Integrated Database for
ARS/AIMPs (IDA) that provides (i) genomic, tran-
scriptomic and proteomic data [mRNA expression, som-
atic mutation, copy number variation (CNV) and
phosphorylation data] of ARS/AIMPs and their interactors
in various cancers and (ii) protein–protein interactions
(PPIs) of ARS/AIMPs.
Materials and methods
Database and website infrastructure
IDA is based on the relational database management sys-
tem for data storage and integration with external data
sources. Gene expression and protein-interaction data are
stored in a MySQL database. Identifiers of all probes on
the microarray types for gene expression data, Ensembl
and dbSNP identifiers for genomic mutation data, identi-
fiers of international protein index or UniProtKB/Swiss-
Prot for protein expression or post-translational modifi-
cations (PTMs) and all identifiers for PPIs in the interac-
tome databases have been converted into NCBI Entrez
identifiers. Using the relationships among different identi-
fiers, we have optimized the database schema
(Supplementary Figure S1) to improve the response time
of the database when gene/protein expression, genomic
mutation, PTM and PPI data are searched for. Moreover,
IDA provides a web-based user interface for data explor-
ation and visualization. Cancer-associated differential ex-
pression, mutation and CNVs of ARS/AIMPs and their
first and second neighbors were summarized using sev-
eral visualization tools, such as two-way heat maps, a
pinwheel-shaped heat map and bar graphs, respectively.
These data for individual genes can be visualized using
profile plots or extracted in a tubular format. Finally,
two different network analysis tools, Cancer-associated
network and Functional modules are servicing. IDA web
site is constructed with PHP 5.3.3, SWFObject v1.5,
MATLAB R2011a, MySQL 5.1.71, CentOS release 6.5
and Apache/2.2.15 (Unix).
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Identification of differentially expressed genes
IDA includes 40 cancer gene expression datasets. For the
36 cancer datasets generated from Affymetrix microarray
platforms, the log2 intensities in each gene expression data-
set were normalized using the GC-RMA normalization
method (15). For the other four datasets generated from
Illumina, ABI and custom microarray platforms, the log2-
intensities were normalized using the quantile normaliza-
tion method (16). For each dataset, the expressed genes
were then identified using a Gaussian mixture model
method as previously described (17). Briefly, in the mixture
modeling, the distribution of the observed probe intensity
(probeset intensity for Affymetrix data) was fitted by two
Gaussian probability density functions: one was for
expressed genes while the other was for non-expressed
genes. We then selected the expressed genes as the ones
whose maximum intensities across all samples in the data-
set were higher than the threshold intensity at which the
two fitted Gaussian probability density functions meet.
To identify differentially expressed genes (DEGs) between
cancer and normal samples, an integrative statistical hy-
pothesis testing was performed (18, 19). Briefly, Student
t-test and log2-median-ratio test were applied to calculate
T values and log2-median-ratios for all the genes.
Empirical distributions of the null hypothesis were then
estimated by performing random permutations of samples
and then by performing the kernel density estimation (20)
to T values and log2-median-ratios resulted from the ran-
dom permutations. Next, the adjusted P values of each
gene for the individual tests were computed by the two-
tailed test using the empirical distribution. The P values
from the two tests were then combined using Stouffer’s
method (19). The DEGs were identified as the genes with
P 0.05. Finally, as the representative P values of the
genes in multiple datasets of each cancer type, the com-
bined P values of genes in individual datasets were sum-
marized using Stouffer’s method (19).
Deregulation and co-association scores for nodes
and edges in the network models
For the nodes (ARS/AIMPs and there first cancer-
associated neighbors) and edges in the ARS/AIMP cancer-
associated network, the two types of cancer association
scores model were estimated. First, the deregulation score
for each node which denotes the representative degree of
deregulation in the 10 cancer types for which gene expres-
sion data were collected. The combined P values of each
node in 10 different cancer types were first calculated.
These P values were then transformed to Z values using
the inverse standard normal cumulative distribution. The
cumulative sum of Z values of its direct interactors
for each node was calculated in each cancer type (21).
Finally, the average of the cumulative sum of Z values
in 10 cancer types was computed as the deregulation
score. Second, the co-association score between an ARS/
AIMP and their first neighbors representing the extent
of co-deregulation in 10 cancer types is estimated as
‘the number of cancer types where the interacting pairs
of ARS/AIMP-first neighbors are commonly differen-
tially expressed’ divided by ‘the total number of cancer
types’.
Identification of key modules in the ARS/AIMP
network model
Key modules in the ARS/AIMP network were identified
using the random walk with restart (RWR) algorithm
previously reported (22). Briefly, in the RWR algorithm,
we used all nodes in the network as the seeds and assigned
equal initial probabilities (pt at t¼ 0) to the seeds. Random
walks then started with the transitions rate of probabil-
ity¼0.75 and then stopped until L1 norm of the difference
between Pt and Ptþ1 (random walk probabilities of the
nodes at t and tþ1, respectively) became <106. To evalu-
ate the significance of pt, we repeated the random walk
process for randomized networks where the edges were
randomly permuted, estimated an empirical null distribu-
tion of Pt resulted from the randomized networks and
P values of Pt for the nodes in the real network by the
right-sided test using the empirical null distribution. From
the ARS/AIMP network, we finally identified a set of sub-
networks including the nodes with P< 0.05 and defined
the subnetworks as key modules.
Identification of evolutionarily conserved motifs in
the ARS/AIMP network model
To identify evolutionarily conserved regulatory motifs, we
first mapped the nodes in the ARS/AIMP network model
for each species into the ortholog groups in eggnog (23)
and then removed redundant interactions and self-
interactions arising from many-to-one mapping. In the net-
work model for each species, regulatory motifs were
searched using the ortholog groups, and the overlapped
ones among the species were identified as evolutionarily
conserved ones. The interactions among the ortholog
groups in the conserved motifs were then converted to all
the possible protein interactions. After the conversion,
only the motifs composed of the interactions existing in the
real interactome were selected. Finally, among them, the
ones including at least one of ARS/AIMPs were selected as
a final list of evolutionarily conserved motifs.
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Results and discussion
Comprehensive data resources of ARS/AIMPs and
their interactors in IDA
Cancer-associated genes
Recently, huge amounts of global genomic, transcriptomic
and proteomic data for cells or tissues of various cancers
have been generated and deposited into numerous data-
bases. Although these data can be useful to understand
association of ARS/AIMPs with cancers, different types of
global data have been stored in separate databases, which
make analyses of ARS/AIMPs inefficient. To resolve this
problem, we collected genomic, transcriptomic, proteomic
and interaction data of ARS/AIMPs and their interactors
from numerous databases and integrated them to IDA. To
facilitate analyses of association of ARS/AIMPs with
cancers, we first defined cancer-associated genes (CAGs)
using NCI cancer gene index (Figure 1, upper left). Among
6955 human genes in the NCI cancer gene index, we se-
lected 3501 CAGs with the following attributes: (i) cancer
associations of the genes should be validated by manual
curation in the literatures; (ii) the genes should have no
conflicting indications regarding their cancer associations;
(iii) cancer associations of the genes should be experimen-
tally validated in human samples and (iv) the genes should





d_With_Disease and Gene_ Anormaly_has_Disease-Re
lat-ed_Function.
Figure 1. Data resources in IDA. IDA contains CAGs and genomic, transcriptomic, proteomic and PPIs for ARS/AIMPs and their first and second neigh-
bor CAGs. First, IDA provides 3501 CAGs selected from the 6955 genes in NCBI cancer gene index based on the filtering criteria (top left). See text for
the criteria. Second, IDA also provides genomic data (CNVs and somatic mutations) for ARS/AIMPs and their neighbors in diverse cancer types,
which were collected from CanGEM, TumorScape, CCLE and COSMIC (bottom left). Third, IDA contains gene expression data of ARS/AIMPs and their
neighbors for 10 cancer types, as well as P values and log2-fold-changes that represent differential expression of the genes in the 10 cancer types
(bottom right). IDA further contains proteomic data (protein abundance and PTMs) collected from dbDEPC, PHOSIDA and PhosPhoSitePlus. Finally,
IDA provides PPIs of ARS/AIMPs and their neighbors collected from 15 interactome databases.
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CAGs interacting with ARS/AIMPs
Mammalian ARS/AIMPs have additional domains to cata-
lytic domains (2). They interact with other molecules
through the additional domains, thereby affecting activities
of cancer-related cellular processes (3). Next, we thus iden-
tified the CAGs that interact with ARS/AIMPs among the
3501 CAGs. To this end, we collected 1 12 596 PPIs from
the following 15 interactome databases with (Figure 1,
upper right): (i) curated PPIs for each of which experimen-
tal evidence was previously reported from human protein
reference database (24), Kyoto Encyclopedia of Genes and
Genomes (25), Biomolecular interaction network database
(BIND) (26), Database of Interacting Proteins (27),
Biological General Repository for Interaction Datasets
(28), Reactome (29), Molecular INTeraction database
(30), IntAct (31), InnateDB (32), Search Tool for the
Retrieval of Interacting Genes/Proteins (STRING, v9.0)
(33) and PharmDB (34) and (ii) predicted PPIs based on
paralog- and ortholog-based PPI prediction and text min-
ing from STRING, BIND, interologous interaction data-
base (I2D) (35), online predicted human interaction
database (36), human PPI map (HiMAP) (37) and human
PPI prediction (38). In addition, the resources that inte-
grate PPIs in individual interactome databases, such as
PSICQUIC (EBI) (39) and NCBI PPI databases, were also
used. On the basis of the collected PPIs, we identified 123
first neighbor CAGs and 1293 second neighbor CAGs of
ARS/AIMPs among the 3501 CAGs.
Transcriptomic data of ARS/AIMPs and their interacting
CAGs
Alteration of expression levels of the genes in cancers sug-
gests their associations with a broad spectrum of cancer
pathophysiological processes. To examine cancer-
associated alteration in gene expression, huge amounts of
gene expression profiles from diverse types of cancers have
been collected (40–43). Thus, we collected 40 cancer ex-
pression profiles for 10 representative cancer types (pan-
creatic, prostate, lung, breast, colon, kidney, head and
neck, hematopoietic and lymphoid, liver and gastric cancer)
(Figure 1, bottom right). The 164 cancer gene expression
datasets were initially collected from the Gene Expression
Omnibus (44) and ArrayExpress (45). Among the 164
datasets, 40 were then selected based on the following cri-
teria: (i) each dataset should include more than 10 normal
and 10 cancer samples and (ii) each cancer type should in-
clude at least two datasets (Supplementary Table S1).
In each dataset, DEGs between cancerous and normal
samples were identified using the integrative statistical
method previously reported (P< 0.05) (17), as described in
Materials and Methods. For each cancer type, we then com-
puted representative P values of the genes as the combined
P values of the genes in multiple datasets of the cancer type
(19) using Stouffer’s method (Materials and Methods). Also,
to summarize expression changes in the 10 types of cancers,
the representative log2-fold-changes of the genes were com-
puted as their averaged log2-fold-changes. For comparative
analysis of ARS/AIMPs and their interacting CAGs, we iden-
tified 1874 non-CAGs, as negative controls, which were not
included in the cancer gene index and also showed no signifi-
cant cancer-associated alterations in gene expression profiles
(i.e. combined P< 0.05 in none of the 10 types of cancers).
The comparison of the representative log2-fold-changes
revealed that ARS/AIMPs and their first and second
neighbors in the 10 types of cancers showed significant
changes in their expression levels, compared with non-CAGs
(Figure 2).
Genomic data of ARS/AIMPs and their interacting CAGs
Recently, a number of studies have showed that somatic
mutations and CNVs were associated with cancer-related
pathophysiological processes (40–43, 46). Thus, to under-
stand cancer-related alterations of ARS/AIMPs and their
interactors in somatic mutations and CNVs, we first ob-
tained CNV data for nine cancer types (skin, gastric, colon,
head and neck, hematopoietic and lymphoid, lung, bone,
soft tissue and uterine) from CanGEM (47) and also from
Tumorscape (48) for 14 cancer types (leukemia and breast,
colorectal, esophageal squamous, lung, liver, ovarian,
prostate and renal cancers and medulloblastoma, melan-
oma, myeloproliferative disorder, glioma and sarcoma)
(Figure 1, bottom left; Supplementary Table S2).
Frequencies of gain and loss for each gene in individual
types of cancers were pre-computed as described previ-
ously (47) and stored in IDA. We then obtained somatic
mutations from cancer cell line encyclopedia (CCLE) (49)
and catalog of somatic mutations in cancer for diverse can-
cer types (50). IDA contains a total of 7 09 008 somatic
mutations including missense, indel, frameshift and non-
sense mutations (1452 for ARS/AIMPs, 5 87 125 for their
interacting CAGs and 1 20 431 for non-CAGs).
Using these data, we compared alteration degrees of
CNVs in ARS/AIMPs, first and second neighbor CAGs and
non-CAGs (Figure 3A). ARS/AIMPs and their interactors
showed significant gains and losses of copy numbers in
nine representative cancers, whereas little variation was
observed in non-CAGs. We further examined gains and
losses of ARS/AIMPs using the CNV data obtained from
CCLE. In total, 18 cases of TARS amplifications were
found in lung cancer cells (Figure 3B). High frequencies of
NARS deletions were observed in several cancer types,
such as large intestine, lung and pancreas cancer cells
(Figure 3C). Especially, 23% of esophagus cancer cells
contained NARS copy number deletions.
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Also, we compared somatic mutations of ARS/AIMPs,
first and second neighbor CAGs and non-CAGs (Figure 4).
The CAG neighbors showed relatively higher frequencies of
somatic mutations (average relative frequency¼ 5.3) than
non-CAGs (average relative frequency¼0.35) in all the can-
cer types examined. Interestingly, the mutation rates of
ARA/AIMPs (average relative frequency¼ 0.35) were also
relatively lower than their CAG neighbors, although ARS/
AIMPs showed significant cancer-related alterations in their
expression (Figure 2). Nonetheless, several ARS/AIMPs
showed relatively high frequency of missense/in-frame indel
mutations in several cancer types, such as endometrium and
prostate cancers (average relative frequencies¼ 0.78 and
0.74, respectively). For example, a total of 209 missense/in-
frame indel mutations of ARS/AIMPs were found in endo-
metrium cancers. Especially, among the mutations, nearly
80 missense mutations of MARS, CARS, LARS and EPRS
were found in the endometrium cancers. Also, the same type
of mutations, including both missense and in-frame deletion
mutations of KARS, were observed with relative frequency
of 0.74 in prostate cancers.
Proteomic data of ARS/AIMPs and their interacting CAGs
Post-translation modifications (PTMs) of ARS/AIMPs and
their interacting CAGs, such as phosphorylation and ubiquiti-
nation, can modulate the interactions of ARS/AIMPs with
CAGs, thereby affecting non-canonical functions of ARS/
AIMPs in disease-related cellular processes. For example,
EPRS, KRS and AIMP2 are dissociated from MSCs by phos-
phorylation and regulate inflammation, metastasis and apop-
tosis, respectively (51–53). Thus, we collected PTMs of ARS/
AIMPs and their interactors, as well as their protein abun-
dances, in diverse types of cancers (Figure 1, bottom right).
First, protein abundance data in 20 cancer types (brain,
breast, cervical, colorectal, esophageal, gall bladder, gastric,
head and neck, liver, lung, ovarian, pancreatic, prostate,
renal, skin, testicular and thyroid cancers and leukemia,
lymphoma and sarcoma) were obtained from dbDEPC (54).
Second, PTM data of ARS/AIMPs and their interactors were
obtained from phosphorylation site database (PHOSIDA)
and PhosPhoSitePlus (55, 56). A total of 375 phosphoryl-
ations for ARS/AIMPs were found in several cancer cells
including cervical, breast and colorectal cancer and leukemia
cells. Additionally, IDA includes 84 acetylations, 410 ubiqui-
tinations, 4 methylations and 1 sumoylation for ARS/AIMPs.
Analytical tools of ARS/AIMPs and their
interactors in IDA
Web-based search and exploration tools
The goal of IDA is to provide not only molecular and inter-
action data of ARS/AIMPs but also analytical tools that
Figure 2. Differential expression of ARS/AIMPs and their neighbors. IDA provides a functionality for exploration of differential expression of the four
groups of the genes in the 10 cancer types: (i) ARS/AIMPs, (ii) and (iii) their first and second neighbor CAGs and (iv) non-CAGs. The color bar for each
group shows sorted log2-fold-changes of the genes in the group. Compared with non-CAGs, the ARS/AIMPs and their interactors showed more sig-
nificant differential expression in the 10 cancer types. The t-test was used to compute P-values representing the significances of the differences be-
tween the mean log2-fold-change values of ARS/AIMPs and non-CAGs. Color bar denotes the gradient of log2-fold-changes of the genes. HLT:
hematopoietic and lymphoid tissue.
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generate network models and then network-driven hypoth-
eses for understanding of cancer-associated functions of
ARS/AIMPs. IDA provides a search tool (‘Detailed search
about ARS’ in Figure 5, center) that allows us to explore
the collected genomic, transcriptomic and proteomic data
for ARS/AIMPs. For example, when the genomic data for
DARS were searched, the search output shows the gen-
omic, proteomic and interaction data of DARS in IDA.
The genomic data showed the gains of copy numbers in
soft tissue cancers, but losses of copy numbers in gastric,
head and neck and soft tissue cancers (Figure 5, top right).
The proteomic data showed the five types of PTMs for
DARS (phosphorylation, acetylation, methylation, ubiqui-
tination and sumoylation), as well as the PTM sites
(Figure 5, middle right): For example, the phosphorylation
data showed five serine (S112, S146, S238, S249 and
S427), three tyrosine (Y24, Y239 and Y245) and one
threonine (T52) phosphorylation sites. Further detailed
information of the PTMs can be obtained through the links
to the original PTM databases.
Moreover, another search tool (‘ARS-CAG interactome
search’ in Figure 5, center) allows us to explore the CAGs
with which ARS/AIMPs interact. For example, the search
output for KARS showed a list of CAGs interacting with
Figure 3. Alterations of copy numbers of ARS/AIMPs and their neighbors. (A) Average frequencies of gains (amplification) and losses (deletion) of
copy numbers in the four groups of the genes in nine representative cancer types using CNV data in CanGEM: (i) ARS/AIMPs, (ii) and (iii) first and se-
cond neighbor CAGs and (iv) non-CAGs. The frequency was defined by the number of amplification cases for the genes in each group divided by the
total number of the genes in the group. (B) Amplification frequencies of ARS/AIMPs in lung cancer cell lines using CNV data in CCLE. (C) Heat map
showing deletion frequencies of ARS/AIMPs in 16 different types of cancer cell lines using CNV data in CCLE. Color bar shows the gradient of deletion
frequency. CNS, central nervous system; HLT, hematopoietic and lymphoid tissue.
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KARS (Figure 5, bottom right). This list of interactors of
KARS can be used to study their KRS-related functions
and pathological implications such as cell
migration (MAPK11/12/14) (52, 57), immune response
(MITF) (57) and Amyotrophic Lateral Sclerosis (SOD1)
(58, 59), supporting the utility of the interactors of ARS/
AIMPs. Finally, the first and second CAG neighbors of
ARS/AIMPs can be explored using the links to the list of
interacting CAGs or the search tool for the
CAGs (‘Detailed search about CAG’ in Figure 5, center).
All the genomic and proteomic data of the CAGs can be
explored, similar to those of ARS/AIMPs shown in
Figure 5. Finally, the interactome of a list of genes with the
molecules in IDA can be obtained using ‘Cancer-
associated network’ in ‘Analysis’ of the ‘Network’ menu
after entering the symbols of the genes (‘Select All’ group
option).
Cancer-associated network models for ARS/AIMPs
An important goal of the tools in IDA is to develop cancer-
associated network models for ARS/AIMPs by integrating
both transcriptomic and interaction data and to generate
hypotheses for mechanisms of ARS/AIMPs in cancer-
related pathophysiological processes based on the network
models. To this end, IDA first provides the tools to develop
cancer-associated network models for ARS/AIMPs
(‘Cancer-associated network’ in ‘Analysis’ of ‘Network’
menu). The network model was generated using ARS/
AIMPs and their first neighbor CAGs and then visualized
using Cytoscape (60) (Figure 5, top left). The nodes (ARS/
Figure 4. Somatic mutations of ARS/AIMPs and their neighbors. Average numbers of somatic mutations in the four groups of the genes in 16 cancer
types using somatic mutation data in CCLE: (i) ARS/AIMPs, (ii) and (iii) first and second neighbor CAGs and (iv) non-CAGs. The mutations were cate-
gorized into the following groups: (i) missense/in-frame InDels, (ii) frameshift, (iii) nonsense, (iv) gain of sequence, (v) complex, (vi) silent and (vii)
unknown mutations. Color bar denotes the gradient of the number of each group of mutations.
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AIMPs and their first neighbor CAGs) in the network
model can be organized into functional modules in each of
which the nodes have the same gene ontology biological
processes (Figure 6A; ‘Cancer-associated network of ARS/
AIMPs and first neighbor CAGs’ in ‘Output’ of ‘Network’
menu). The nodes in the network model can have different
degrees of contributions to cancer-related pathophysio-
logical processes. To represent the different degrees of
Figure 6. Evolutionarily conserved motifs in the ARS/AIMP network model. (A) ARS/AIMPs cancer network model showing 23 ARS/AIMPs and 123
first neighbor CAGs. Colored nodes represent ARS/AIMPs (dark orange) and their first neighbors (orange). Node sizes represent the average deregu-
lation scores in the 10 cancer types (Materials and Methods). Nodes were grouped, such that the nodes involved in the same cellular process, accord-
ing to gene ontology biological process annotations, belonged to a functional module denoted by the orange background. (B) Two key functional
modules identified using the random walk-based method. (C) Evolutionarily conserved motifs in the ARS/AIMP network models constructed in
human, fly, bacteria and yeast. The motifs conserved between human and the other three species were shown.
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node contributions to the cancer-related processes, we esti-
mated deregulation score indicating representative degree of
deregulation in the 10 cancer types for which gene expression
data were collected (Materials and Methods). The inter-
actions (edges) between ARS/AIMPs and CAGs in the net-
work model can have different degrees of associations with
cancers. To represent the different degree of cancer associ-
ations for each pair of ARS/AIMP and its CAG interactor,
we estimated the co-association score for the interacting pair
that represents the extent of co-deregulation in the 10 cancer
types. The network model can reveal a set of the linked nodes
with high deregulation and co-association scores, which can
be considered as a functional module that can significantly
contribute to cancer-related pathophysiological processes rep-
resented in the network model.
Key functional modules of ARS/AIMPs in the network
model
To understand functions of ARS/AIMPs defined by their
interactions with the CAGs, it is important to identify the
sets of the ARS/AIMP-CAG nodes densely connected
with high deregulation and co-association scores, which
are referred to as key functional modules of ARS/AIMPs.
These modules should include at least one ARS/AIMP
and its interaction with the CAGs to examine cancer-
related functions of ARS/AIMPs. Thus, IDA provides a
random walk-based method to effectively identify the key
ARS/AIMP-CAG functional modules (‘Functional mod-
ules’ in ‘Analysis’ of ‘Network’ menu). This method per-
forms random walks based on the co-association scores
and then identifies a set of the nodes that should include
more than at least one ARS/AIMP with high residence
probabilities after a certain period of time. For the net-
work model in Figure 6A, the random walk-based
method generated two key functional ARS/AIMP-CAG
modules (Figure 6B; ‘Functional modules for cancer-asso-
ciated network of ARS/AIMPs and first neighbor CAGs’
in ‘Output’ of ‘Network’ menu). These modules (GARS
and MARS subnetworks) show the links of the ARSs to
(i) NFKB pathway through their interactions with
NFKB2, IKBKG/E and MCC (61, 62) and (ii) transcrip-
tional regulators (ELF3 and BRF2). This suggests poten-
tial roles of GARS and MARS in NFKB signaling and
transcriptional regulation. Furthermore, these modules
show the possible association of the ARSs in the immune
response (HLA-B and TRAF6) and cell migration (CD44
and MCC).
Evolutionary analysis of the cancer-associated network for
ARS/AIMPs
In addition to the random walk-based method mentioned
above, evolutionary analysis of the cancer-associated
network for ARS/AIMP can be applied to the network
model to identify core regulatory motifs of ARS/AIMPs,
assuming that the core regulatory motifs should be con-
served across different species. To this end, we collected
PPIs in four different species, Escherichia coli,
Saccharomyces cerevisiae, Drosophila melanogaster and
Homo sapiens (Supplementary Table S3) and then recon-
structed ARS/AIMP network models using first and second
neighbors of ARS/AIMPs in individual species. Next, we
identified evolutionarily conserved network motifs recur-
ring in the network models of individual species
(‘Evolutionarily conserved motifs’ in ‘Analysis’ of
‘Network’ menu). Among the identified motifs, we focused
on the ones conserved in human to understand roles of
ARSs in human networks (‘Evolutionarily conserved
motifs of ARS/AIMPs and first and second neighbor
CAGs’ in ‘Output’ of ‘Network’ menu). The identified
motifs were mostly conserved in two species, Yeast-
Human (4 motifs), Fly-Human (4 motifs) and Bacteria-
Human (2 motifs) (Figure 6C).
These evolutionarily conserved motifs suggest that the
components in the motifs may form functional complexes.
For instance, the motif consisting of MARS, AIMP1 and
QARS was suggested to be conserved among yeast, fly and
human. These three proteins are the known components
forming MSC with other ARSs in human (63). In the
human form, the structural or functional association
AIMP1 with QARS and MARS were experimentally dem-
onstrated (4, 64). The primitive complex form was found
in yeast consisting of MARS, Acr1p (homolog of AIMP1)
and EARS (65) and the functional significance of this com-
plex was studied in-depth (66). The potential interactions
among these three proteins were also suggested in fly (67),
indicating that functional implications of the fly com-
plex can be obtained from the in-depth studies
conducted in other organisms. Thus, the conserved
motif analysis can be useful to predict how these ARS-con-
taining macromolecular complexes have evolved from uni-
cellular to multicellular organisms in their structure and
function.
The nodes in the conserved motifs are involved in a
broad spectrum of cellular processes, including cell cycle
and DNA repair, protein modification (e.g. neddylation)
and localization, signal transduction and response to stress
(e.g. NFKB pathway). These results indicate that ARSs can
play potential roles in these processes. Interestingly, the
link of ARS/AIMPs to NFKB pathway was predicted by
both the random walk-based method and the evolutionary
analysis of ARS/AIMP networks. Many motifs
conserved in higher organisms, as well as a broad spectrum
of cellular processes associated with these motifs, are con-
sistent to previous findings that they can acquire
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evolutionarily new functions by the addition of new do-
mains (68–70).
Conclusions
Several studies have discovered diverse implications of
ARS/AIMPs in human diseases. However, there is still the
lack of data resources and tools that can be used to analyze
potential functional roles of ARS/AIMPs in human
diseases. IDA was developed to provide a broad spectrum
of genomic (somatic mutations and CNVs), transcriptomic
(mRNA expression), proteomic (protein abundance and
PTMs) and interactome data (PPIs) from 25 existing DBs
(Figure 1) for ARS/AIMPs and their interactors. However,
IDA is not simply assemblies of information available in
the 25 DBs that provide intact or federated links to the ori-
ginal data. The collected data were reprocessed, designed
and integrated in such a way to facilitate the integrative
analyses (analyses of cancer-related changes in gene and
protein abundances and genomic variations, network ana-
lysis, functional modules and evolutionary motif analysis)
and explorative analyses (navigation and visualization of
the information) of cancer-related ARS data. When cancer-
related alterations in abundances and genomic variations
are discovered for ARS/AIMPs and/or their interactors,
IDA can be used to evaluate whether the discovery was fur-
ther investigated or not. Furthermore, IDA provides a bat-
tery of analytical tools for the integrative analyses and also
the outputs from the integrative analyses. The outputs (e.g.
network modules) can be used to generate hypotheses for
functions of ARS/AIMPs or mechanisms for such functions
in cancers, thereby providing new insights into cancer-
related functions of ARS/AIMPs. Currently, IDA provides
cancer-related data only and is thus limited to investigation
of association of ARS/AIMPs with cancers. However, it
will be expanded to include genomic, transcriptomic and
proteomic data collected from metabolic and neurological
diseases. Recently, a number of studies have shown im-
portant roles of ARS/AIMPs in pathogenesis of diverse dis-
eases. Therefore, IDA can serve as a comprehensive
resource of data and tools for studies of ARS/AIMPs that
can facilitate elucidation of unknown functions of ARS/
AIMPs in disease pathogenesis.
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